| Drug Name | spironolactone and renin-angiotensin system drugs |
|---|---|
| Drug Class |
Anti-hypertension
Diuretics
|
| Risk minimization type |
Safety communication
|
| Specialty (Theraputic area) |
Cardiology
|
| Risk |
Risk of Severe Hyperkalemia with co-adminster with RAAS drugs |
| safety communication |
|